Fig. 5
From: The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
Longitudinal assessment of mean CSF αSyn values at baseline, 12-months and 24-months in (a) a pooled MCI and Alzheimer’s disease (AD) patient group classified as either APOEε4 carriers (baseline to 12-months n = 58, 12-months to 24-months n = 47) or non-carriers (baseline to 12-months n = 21, 12-months to 24-months n = 19). b the MCI-AD patient group classified as either APOEε4 carriers (baseline to 12-months n = 19, 12-months to 24-months n = 16) or non-carriers (baseline to 12-months n = 7, 12-months to 24-months n = 7), c the MCI-AD patient group classified as either APOEε4 non-carriers (baseline to 12-months n = 7, 12-months to 24-months n = 7), heterozygotes (baseline to 12-months n = 8, 12-months to 24-months n = 7) or homozygotes (baseline to 12-months n = 11, 12-months to 24-months n = 9). P-values within patient groups over 1-year intervals are shown in red along the trend lines, and between-group p-values are indicated in black. P-values were calculated using repeated measures MANOVA analysis of log-transformed data. MCI-AD = MCI patients who converted to Alzheimer’s disease at the 24-month follow up